KEKULE PHARMA LTD

Company Type: Factory (Manufacturer)

Company Introduction:

Kekule Pharma Ltd. is a prominent pharmaceutical company based in India, specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs), intermediates, and various finished dosage forms. Established with a commitment to quality and innovation, the company operates state-of-the-art manufacturing facilities that comply with international regulatory standards, including cGMP. Kekule Pharma focuses on research and development to produce a diverse range of therapeutic products for both domestic and international markets. Their product portfolio encompasses a wide array of pharmaceutical compounds, and they are recognized for their robust production capabilities, stringent quality control systems, and dedication to contributing to global healthcare.

Kekule Pharma Ltd, an Indian company, manufactures and sells a wide range of Active Pharmaceutical Ingredients (APIs) and API Intermediates. Their product portfolio primarily consists of bulk drugs used by other pharmaceutical companies to produce finished medicinal formulations.

Their products span various therapeutic categories and include:

Gastrointestinal APIs:

Pantoprazole Sodium Sesquihydrate

Esomeprazole Magnesium Trihydrate

Rabeprazole Sodium

Omeprazole

Lansoprazole

Cardiovascular and Anticoagulant APIs:

Rivaroxaban

Apixaban

Dabigatran Etexilate Mesylate

Valsartan

Telmisartan

Losartan Potassium

Antidiabetic APIs:

Sitagliptin Phosphate Monohydrate

Vildagliptin

Linagliptin

Empagliflozin

Dapagliflozin Propanediol Monohydrate

Antiviral APIs:

Sofosbuvir

Remdesivir

Favipiravir

Molnupiravir

Immunosuppressant and Immunomodulator APIs:

Tacrolimus

Sirolimus

Everolimus

Mycophenolate Mofetil

Oncology APIs (various kinase inhibitors, PARP inhibitors, etc.):

Osimertinib

Palbociclib

Abemaciclib

Ibrutinib

Olaparib

Dasatinib

Imatinib Mesylate

Neurological Disorder APIs:

Pregabalin

Gabapentin

Tizanidine HCl

Biologics (Monoclonal Antibody APIs):

Adalimumab (API)

Pembrolizumab (API)

Rituximab (API)

Trastuzumab (API)